{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:16:42Z","timestamp":1790266602531,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Ju-295\/9-1 (SPP1463)"],"award-info":[{"award-number":["Ju-295\/9-1 (SPP1463)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004875","name":"DFG","doi-asserted-by":"publisher","award":["Ju-295\/9-2 (SPP1463)"],"award-info":[{"award-number":["Ju-295\/9-2 (SPP1463)"]}],"id":[{"id":"10.13039\/100004875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004875","name":"DFG","doi-asserted-by":"publisher","award":["Ju-295\/13-1"],"award-info":[{"award-number":["Ju-295\/13-1"]}],"id":[{"id":"10.13039\/100004875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004875","name":"DFG","doi-asserted-by":"publisher","award":["Si 846\/13-1"],"award-info":[{"award-number":["Si 846\/13-1"]}],"id":[{"id":"10.13039\/100004875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>We designed and synthesized carbamates of the clinically-approved HDAC (histone deacetylase) inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in order to validate our previously-proposed hypothesis that these carbamates might serve as prodrugs for hydroxamic acid containing HDAC inhibitors. Biochemical assays proved our new compounds to be potent inhibitors of histone deacetylases in vitro, and they also showed antiproliferative effects in leukemic cells. These results, as well as stability analysis led to the suggestion that the intact carbamates are inhibitors of histone deacetylases themselves, representing a new zinc-binding warhead in HDAC inhibitor design. This suggestion was further supported by the synthesis and evaluation of a carbamate derivative of the HDAC6-selective inhibitor bufexamac.<\/jats:p>","DOI":"10.3390\/molecules23020321","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T06:45:40Z","timestamp":1517553940000},"page":"321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition"],"prefix":"10.3390","volume":"23","author":[{"given":"Kristina","family":"King","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstra\u00dfe 25, 79104 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander-Thomas","family":"Hauser","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstra\u00dfe 25, 79104 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7335-7041","authenticated-orcid":false,"given":"Jelena","family":"Melesina","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Stra\u00dfe 4, 06120 Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-9261","authenticated-orcid":false,"given":"Wolfgang","family":"Sippl","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Stra\u00dfe 4, 06120 Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-7716","authenticated-orcid":false,"given":"Manfred","family":"Jung","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstra\u00dfe 25, 79104 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Keller, K., and Jung, M. (2014). Histone Deacteylase (HDAC) Inhibitors in Recent Clinical Trials for Cancer Therapy, Springer.","DOI":"10.1007\/978-3-642-38404-2_10"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_3","first-page":"721","article-title":"Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101","volume":"2","author":"Plumb","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2013.03.059","article-title":"Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells","volume":"434","author":"Qiao","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_6","first-page":"22","article-title":"Romidepsin for the Treatment of Peripheral T-Cell Lymphoma","volume":"6","author":"Barbarotta","year":"2015","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/17474086.2015.983065","article-title":"Panobinostat: A review of trial results and future prospects in multiple myeloma","volume":"8","author":"Libby","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/cmdc.201100007","article-title":"Carbamate prodrug concept for hydroxamate HDAC inhibitors","volume":"6","author":"Schlimme","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.bmc.2013.11.053","article-title":"Synthesis\/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain","volume":"22","author":"Seki","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1021\/jm00008a020","article-title":"The synthesis of N-hydroxy-N\u2032-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells","volume":"38","author":"Stowell","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00304940109356608","article-title":"A new facile and expeditious synthesis of N-hydroxy-N\u2032-phenyloctanediamide, a potent inducer of terminal cytodifferentiation","volume":"33","author":"Mai","year":"2001","journal-title":"Org. Prep. Proced. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1016\/S0040-4039(98)01330-6","article-title":"An efficient new protocol for the formation of unsymmetrical tri- and tetrasubstituted ureas","volume":"39","author":"Batey","year":"1998","journal-title":"Tetrahedron Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/S0040-4039(99)00302-0","article-title":"A new protocol for the formation of carbamates and thiocarbamates using carbamoyl imidazolium salts","volume":"40","author":"Batey","year":"1999","journal-title":"Tetrahedron Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1016\/j.tetlet.2003.08.026","article-title":"Carbamoylimidazolium salts as diversification reagents: An application to the synthesis of tertiary amides from carboxylic acids","volume":"44","author":"Grzyb","year":"2003","journal-title":"Tetrahedron Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1016\/j.tet.2005.05.056","article-title":"Carbamoylimidazolium and thiocarbamoylimidazolium salts: Novel reagents for the synthesis of ureas, thioureas, carbamates, thiocarbamates and amides","volume":"61","author":"Grzyb","year":"2005","journal-title":"Tetrahedron"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ymeth.2005.03.003","article-title":"In vitro assays for the determination of histone deacetylase activity","volume":"36","author":"Heltweg","year":"2005","journal-title":"Methods"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Watson, P.J., Millard, C.J., Riley, A.M., Robertson, N.S., Wright, L.C., Godage, H.Y., Cowley, S.M., Jamieson, A.G., Potter, B.V.L., and Schwabe, J.W.R. (2016). Insights into the activation mechanism of class I HDAC complexes by inositol phosphates. Nat. Commun., 7.","DOI":"10.1038\/ncomms11262"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.bmcl.2010.03.091","article-title":"Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides","volume":"20","author":"Bressi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/nar\/27.9.2057","article-title":"A non-isotopic assay for histone deacetylase activity","volume":"27","author":"Hoffmann","year":"1999","journal-title":"Nucleic Acids Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/1078-0432.CCR-07-4427","article-title":"Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay","volume":"14","author":"Bonfils","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Marek, M., Kannan, S., Hauser, A.T., Moraes Mourao, M., Caby, S., Cura, V., Stolfa, D.A., Schmidtkunz, K., Lancelot, J., and Andrade, L. (2013). Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003645"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_26","unstructured":"(Schr\u00f6dinger Suite 2012 Protein Preparation Wizard, 2012). Schr\u00f6dinger Suite 2012 Protein Preparation Wizard, Epik Version 2.3; Impact Version 5.8; Prime Version 3.1."},{"key":"ref_27","unstructured":"(Molecular Operating Environment (MOE), 2012). Molecular Operating Environment (MOE), 2012.10."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1021\/acs.jmedchem.5b01478","article-title":"Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis","volume":"59","author":"Heimburg","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.jmedchem.5b01493","article-title":"Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors","volume":"59","author":"Senger","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/j.bmc.2011.06.030","article-title":"Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors","volume":"19","author":"Whitehead","year":"2011","journal-title":"Bioorg. Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/2\/321\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:53:34Z","timestamp":1760194414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/2\/321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["molecules23020321"],"URL":"https:\/\/doi.org\/10.3390\/molecules23020321","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]}}}